Search results
Results from the WOW.Com Content Network
Andrew S. Levey (born September 16, 1950) is an American nephrologist who transformed chronic kidney disease (CKD) clinical practice, research, and public health by developing equations to estimate glomerular filtration rate (GFR) (renal function), and leading the global standardization of CKD definition and staging.
Treatment efforts may involve many clinical and diagnostic manoeuvers, such as trying to decrease phosphate, [7] normalize vitamin D (calcidiol levels) or decrease PTH and/or alkaline phosphatase levels. [8] However, there is an important lack of randomized clinical studies and recent guidelines (KDIGO 2017) have been recently released on the ...
Kidney Disease Improving Global Outcomes – KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease [58] A glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m 2 is considered normal without chronic kidney disease if there is no kidney damage present.
Clinical assessment can be used to assess the function of the kidneys. This is because a person with abnormally functioning kidneys may have symptoms that develop. For example, a person with chronic kidney disease may develop oedema due to failure of the kidneys to regulate water balance.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1–150.
The NKF also publishes the Kidney Dialysis Outcomes Quality Initiative, KDOQI, a comprehensive set of clinical practice guidelines. [citation needed] The NKF has been a vocal advocate for increasing some forms of kidney transplantation, though it opposes organ donations wherein donors are compensated for their donation. [6]
Since the diagnosis of these bone abnormalities cannot be obtained correctly by current clinical, biochemical, and imaging methods (including measurement of bone-mineral density), bone biopsy has been, and still remains, the gold standard analysis for assessing the exact type of renal osteodystrophy.
Clinical Phase III studies showed that sucroferric oxyhydroxide achieves and maintains phosphate levels in compliance with the KDOQI guidelines. [19] [20] The reduction in serum phosphate levels of sucroferric oxyhydroxide-treated patients was non-inferior to that in sevelamer-treated patients. The required daily pill burden was lower with ...